摘要
Abstract
Objective To assess the effect of thrombin-activatable fibrinolysis inhibitor (TAFI), plasminogen activator inhibitor-1 (PAI-1) in non-obesity type 2 diabetic patients, and to investigate the relationship between TAFI, PAI-1 and clinical parameters of metabolism. Methods
The individuals confined to the enrolling criteria were divided into three groups. Group 1 included 57 cases of non-obesity type 2 diabetic patients with vascular lesion; group 2 consisted of 39 non-obesity type 2 diabetic patients with no vascular lesion; and the 80 enrolled healthy individuals were regarded as normal control group. The levels of plasma TAFI, PAI-1, von Wille-brand factor (vWF) and fibrinogcn (FIB) were measured. The changes of fasting blood glucose, glycosylated hemoglobin, fasting insulin, body mass index and lipid metabolism- indicators were detected as well. Results Compared with the plasmic levels of TAFI, PAI-1, vWF, FIB in normal control group, the levels in group 1 were obviously higher (P <0.01), and TAFI, PAI-1, vWF, FIB in group 2 dramatically increased with significant difference (P <0.05). Compared with the plasmic levels of TAFI, PAI-1 in group 2, the levels in group 1 obviously increased (P <:0.05). The significantly positive correlations were found between plasmic TAFI level and serum fasting blood glucose levels, or serum glycosylated hemoglobin levels (r=0.29, P <005; r=0.71, P <0.01 respectively). Another positive correlation was also observed between the plasmic PAI-1 level and body mass index (r= 0.33, P <0.05). There was no relationship between the changes of plasma PAI-1 and TAFI levels. Conclusion The findings suggest that the coagulation activity can be enhanced in non-obesity type 2 diabetic patients accompanied by decreased activity of fibrinoly-sis. The level increase of plasma TAFI is related with the long-term high blood sugar, which is a valuable marker to assess the deterioration of disease, and the fat accumulation is involved in the PAI-1 level increase in disease.关键词
凝血酶激活的纤溶抑制物/纤溶酶原激活剂抑制物-1/非肥胖型2型糖尿病/血管性假性血友病因子Key words
thrombin-activatable fibrinolysis inhibitor/ plasminogen activator inhibitor-1/ non-obesity type 2 diabetic patients/ von Willebrand factor分类
医药卫生
